June 27, 2008 Journal article Open Access

Trumbo PhD, Paula R.; Ellwood, Kathleen C.

JSON Export

{
  "files": [
    {
      "links": {
        "self": "https://zenodo.org/api/files/97d24fff-8a37-446a-b478-de637f0c9655/article.pdf"
      }, 
      "checksum": "md5:198f558d81ae89c3338a0533e40aaa42", 
      "bucket": "97d24fff-8a37-446a-b478-de637f0c9655", 
      "key": "article.pdf", 
      "type": "pdf", 
      "size": 72283
    }
  ], 
  "owners": [
    13380
  ], 
  "doi": "10.1111/j.1753-4887.2006.tb00220.x", 
  "stats": {
    "version_unique_downloads": 204.0, 
    "unique_views": 236.0, 
    "views": 238.0, 
    "version_views": 238.0, 
    "unique_downloads": 204.0, 
    "version_unique_views": 236.0, 
    "volume": 15179430.0, 
    "version_downloads": 210.0, 
    "downloads": 210.0, 
    "version_volume": 15179430.0
  }, 
  "links": {
    "doi": "https://doi.org/10.1111/j.1753-4887.2006.tb00220.x", 
    "latest_html": "https://zenodo.org/record/1230786", 
    "bucket": "https://zenodo.org/api/files/97d24fff-8a37-446a-b478-de637f0c9655", 
    "badge": "https://zenodo.org/badge/doi/10.1111/j.1753-4887.2006.tb00220.x.svg", 
    "html": "https://zenodo.org/record/1230786", 
    "latest": "https://zenodo.org/api/records/1230786"
  }, 
  "created": "2018-04-26T17:53:25.774497+00:00", 
  "updated": "2020-01-20T17:06:38.162099+00:00", 
  "conceptrecid": "1230785", 
  "revision": 5, 
  "id": 1230786, 
  "metadata": {
    "access_right_category": "success", 
    "doi": "10.1111/j.1753-4887.2006.tb00220.x", 
    "description": "The labeling of both health claims that meet significant scientific agreement (SSA) and qualified health claims on conventional foods and dietary supplements requires pre-market approval by the US Food and Drug Administration (FDA). Approval by the FDA involves, in part, a thorough review of the scientific evidence to support an SSA or a qualified health claim. This article discusses FDA's evidence-based review of the scientific evidence on the role of chromium picolinate supplements in reducing the risk of type 2 diabetes. Based on this evidence-based review, FDA issued a letter of enforcement discretion for one qualified health claim on chromium picolinate and risk of insulin resistance, a surrogate endpoint for type 2 diabetes. The agency concluded that the relationship between chromium picolinate intake and insulin resistance is highly uncertain.", 
    "license": {
      "id": "CC0-1.0"
    }, 
    "title": "Chromium Picolinate Intake and Risk of Type 2 Diabetes: An Evidence\u2010Based Review by the United States Food and Drug Administration", 
    "relations": {
      "version": [
        {
          "count": 1, 
          "index": 0, 
          "parent": {
            "pid_type": "recid", 
            "pid_value": "1230785"
          }, 
          "is_last": true, 
          "last_child": {
            "pid_type": "recid", 
            "pid_value": "1230786"
          }
        }
      ]
    }, 
    "publication_date": "2008-06-27", 
    "creators": [
      {
        "name": "Trumbo PhD, Paula R."
      }, 
      {
        "name": "Ellwood, Kathleen C."
      }
    ], 
    "access_right": "open", 
    "resource_type": {
      "subtype": "article", 
      "type": "publication", 
      "title": "Journal article"
    }
  }
}